entertainment -WSS

entertainment

author：entertainment 2025-09-28 00:50:57 - browse：94

An ALS patient receives support. -- health coverage from STAT — Adobe

Years of polarizing scientific discourse and bruising online debate will come to a head next week when advisers to the Food and Drug Administration weigh in on NurOwn, a potential treatment to slow the progression of ALS that has bitterly divided physicians and patient advocates.

On Sept. 27, a panel of experts will consider the convoluted data supporting the potential approval of NurOwn, a stem-cell therapy the FDA previously refused to even consider. To some physicians, the drug’s failure to show significant benefits in clinical studies leaves approval out of the question. Others, including the influential ALS Association, say NurOwn’s manufacturer, a small biotech firm called BrainStorm Cell Therapeutics, hasn’t disclosed enough information to properly determine the medicine’s value.

Another group of patients and doctors argue that NurOwn’s supporting evidence, while problematic, justifies making it available to the roughly 30,000 ALS patients in the U.S., people for whom there is currently no hope of arresting an incurable disease that gradually erodes motor function and leads to death within about five years of diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Leon Gautier, last member of French D

knowledge

WSS

Celiac disease study examines precisely how gluten triggers injury

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

Trump pressured former Arizona governor to overturn 2020 election results: Sources

Does aspartame cause cancer? What new WHO guidance says

Global childhood vaccinations edge closer to pre

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

entertainment

entertainment

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

Jerome Adams on the need for new antivirals for Covid

4 dead, 2 in stable condition in Philadelphia shooting: Police

Drug repurposing or repositioning? The language matters

Congress likely to miss an opportunity to fix drug shortages issue

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

NASA releases new images of 'fingerprint

Medical records are filled with copy

Global childhood vaccinations edge closer to pre

focus

Who gets to use the title 'doctor'?

Churchill Downs extends trainer Bob Baffert's ban through 2024

Russians and Belarusians back at Wimbledon as war in Ukraine continues

Masked assailants attack a journalist and a lawyer in Russia's Chechnya province

Does aspartame cause cancer? What new WHO guidance says

Masked assailants attack a journalist and a lawyer in Russia's Chechnya province

explore

hotspot

knowledge

focus